| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22065 |
| Drug |
Olaparib |
| Brand |
Lynparza® |
| Indication |
As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. |
| Rapid review commissioned |
26/10/2022 |
| Rapid review completed |
20/10/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
26/10/2022 |
| Pre-submission consultation with Applicant |
13/12/2022 |
| Full submission received from Applicant |
27/09/2023 |
| Preliminary review sent to Applicant |
09/05/2024 |
| NCPE assessment re-commenced |
06/06/2024 |
| Follow-up to preliminary review sent to Applicant |
05/07/2024 |
| NCPE assessment re-commenced |
11/07/2024 |
| Factual accuracy sent to Applicant |
20/08/2024 |
| NCPE assessment re-commenced |
27/08/2024 |
